Skip to Main Content

++

INTRODUCTION

++

pegloticase (peg-loe-ti-kase)

Krystexxa

Classification

Therapeutic: antigout agents

Pharmacologic: enzymes

++
Indications
++

Treatment of chronic gout in adults who have not responded to/cannot tolerate xanthine oxidase inhibitors, including allopurinol.

++
Action
++

Consists of recombinant uricase covalently bonded to monomethoxypoly (ethylene glycol) [mPEG]); uricase catalyzes the oxidation of uric acid to allantoin, a water-soluble by-product that is readily excreted in urine. Therapeutic Effects: ↓ serum uric acid levels with resultant ↓ in attacks of gout and its sequelae.

++
Adverse Reactions/Side Effects
++

CV: chest pain. EENT: nasopharyngitis. GI: nausea, constipation, vomiting. Derm: contusion/ecchymoses. Metab: gout flare. Misc: ALLERGIC REACTIONS, INCLUDING ANAPHYLAXIS, INFUSION REACTIONS.

++

PHYSICAL THERAPY IMPLICATIONS

++
Examination and Evaluation
++

  • Monitor signs of allergic reactions and anaphylaxis, including pulmonary symptoms (tightness in the throat and chest, wheezing, cough dyspnea) or skin reactions (rash, pruritus, urticaria). Be especially alert for allergy-like responses that occur during and after administration (infusion related reactions). Notify physician or nursing staff immediately of any signs of hypersensitivity.

  • If treating gouty arthritis, periodically assess impairments (pain, range of motion), functional ability, and disability to help document whether drug therapy is successful. Report any increase in symptoms that occur when initiating drug therapy (gout flare).

  • Monitor any chest pain and attempt to determine if pain is drug-induced or caused by cardiovascular dysfunction (e.g., angina that occurs during exercise). Report severe or unexplained chest pain.

++
Interventions
++

  • If treating arthritic conditions, implement appropriate manual therapy techniques, physical agents, therapeutic exercises, and orthotic/assistive devices to reduce pain, improve function, and augment the effects of drug therapy.

++
Patient/Client-Related Instruction
++

  • Instruct patient and family/caregivers to report other troublesome side effects such as severe or prolonged irritation of the nose or pharynx, skin reactions (contusions, bruising), and GI problems (nausea, vomiting, constipation).

++
Pharmacokinetics
++

Absorption: IV administration results in complete bioavailability.

++

Distribution: Unknown.

++

Metabolism and Excretion: Unknown.

++

Half-life: Unknown.

++

Table Graphic Jump Location
Favorite Table | Download (.pdf) | Print

TIME/ACTION PROFILE (effects on serum uric acid)

ROUTE ONSET PEAK DURATION
IV rapid within 24 hr >300 hr

++
Contraindications/Precautions
++

Contraindicated in: Glucose-6-phosphate dehydrogenase (G6PD) deficiency (risk of hemolysis and methemoglobinemia). Lactation: Breast-feeding is not recommended.

++

Use Cautiously in: Congestive heart failure (may ↑ risk of exacerbation); Retreatment after a drug-free interval (↑ risk of allergic reactions, monitor carefully); Geri: Elderly patients may be more sensitive to drug effects; OB: Use during pregnancy only if clearly needed; Pedi: Safe and effective use in children <18 yr not established.

++
Interactions
++

Drug-Drug: May interfere with the action of other PEG-containing therapies.

...

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.